Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Phase 1

Not yet recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Drug: Propranolol
Radiation: Radiation Therapy
Procedure: Surgical Procedure

First Posted Date: 2024-11-01

Last Posted Date: 2025-06-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT06670976

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Phase 2

Recruiting

Conditions: Extramedullary Disease in Multiple Myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Biological: Mezigdomide
Drug: Carfilzomib
Drug: Dexamethasone
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Computed Tomography Assisted Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2024-10-04

Last Posted Date: 2025-06-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 28

Registration Number: NCT06627751

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Cxcr1/2 Inhibitor SX-682
Drug: Daratumumab and Recombinant Human Hyaluronidase
Drug: Carfilzomib
Drug: Dexamethasone
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-10-01

Last Posted Date: 2025-04-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT06622005

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors

Not Applicable

Recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm

Interventions: Other: Exercise Intervention
Other: Medical Device Usage and Evaluation
Other: Nutritional Intervention
Other: Physical Performance Testing
Other: Questionnaire Administration

First Posted Date: 2024-08-21

Last Posted Date: 2025-05-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 150

Registration Number: NCT06565260

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Phase 3

Recruiting

Conditions: Oligometastasis
Prostate Cancer
Lung Cancer
Colo-rectal Cancer

Interventions: Procedure: Stereotactic Ablative Radiotherapy
Other: Best Practice

First Posted Date: 2024-08-20

Last Posted Date: 2025-01-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 800

Registration Number: NCT06563388

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Recruiting

Conditions: Malignant Solid Neoplasm
Breast Carcinoma
Malignant Thoracic Neoplasm
Kidney Carcinoma

Interventions: Procedure: Functional Near-Infrared Spectroscopy
Other: Questionnaire Administration
Other: Virtual Technology Intervention

First Posted Date: 2024-06-13

Last Posted Date: 2025-04-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 220

Registration Number: NCT06456411

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Locally Advanced Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Tamoxifen

First Posted Date: 2024-05-30

Last Posted Date: 2025-06-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 31

Registration Number: NCT06434064

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Phase 1

Not yet recruiting

Conditions: Stage IV Lung Cancer
Limited-stage Small-cell Lung Cancer
Stage IIIA Lung Cancer
Extensive-stage Small-cell Lung Cancer
Lung Non-Small Cell Carcinoma

Interventions: Other: Radioconjugate
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Biospecimen Collection

First Posted Date: 2024-05-23

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT06427369

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Not Applicable

Recruiting

Conditions: Metastatic Bladder Carcinoma
Unresectable Bladder Carcinoma
Locally Advanced Bladder Carcinoma
Stage IV Bladder Cancer AJCC v8
Stage III Bladder Cancer AJCC v8

Interventions: Procedure: Assessment of Distress
Other: Consultation Visit
Other: Nutritional Assessment
Other: Questionnaire Administration
Other: Supportive Care

First Posted Date: 2024-05-16

Last Posted Date: 2025-03-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 160

Registration Number: NCT06414317

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Not Applicable

Recruiting

Conditions: Breast Carcinoma
Breast Ductal Carcinoma in Situ

Interventions: Behavioral: Patient Navigation
Other: Questionnaire

First Posted Date: 2024-04-05

Last Posted Date: 2024-12-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 126

Registration Number: NCT06350500

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy